publication . Article . 2016

Dissociation of Down syndrome and Alzheimer's disease effects with imaging

Matthews, Dawn C.; Lukic, Ana S.; Andrews, Randolph D.; Marendic, Boris; Brewer, James; Rissman, Robert A.; Mosconi, Lisa; Strother, Stephen C.; Wernick, Miles N.; Mobley, William C.; ...
Open Access
  • Published: 01 Jun 2016 Journal: Alzheimer's & Dementia: Translational Research & Clinical Interventions, volume 2, issue 2, pages 69-81 (issn: 2352-8737, Copyright policy)
  • Publisher: Elsevier BV
Abstract
AbstractIntroductionDown Syndrome (DS) adults experience accumulation of Alzheimer's disease (AD)–like amyloid plaques and tangles and a high incidence of dementia and could provide an enriched population to study AD-targeted treatments. However, to evaluate effects of therapeutic intervention, it is necessary to dissociate the contributions of DS and AD from overall phenotype. Imaging biomarkers offer the potential to characterize and stratify patients who will worsen clinically but have yielded mixed findings in DS subjects.MethodsWe evaluated 18F fluorodeoxyglucose positron emission tomography (PET), florbetapir PET, and structural magnetic resonance (sMR) im...
Subjects
free text keywords: Down syndrome, Alzheimer's, Imaging, Amyloid, AV-45, Glucose metabolism, FDG, PET, MRI, Clinical trials, Prodromal, Biomarker initiative, DSBI, Classifier, NPAIRS, Featured Article
Related Organizations
Funded by
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
,
NSF| SBIR Phase II: Early and Specific Dementia Diagnosis Using Imaging and Pattern Classification Software
Project
  • Funder: National Science Foundation (NSF)
  • Project Code: 1256638
  • Funding stream: Directorate for Engineering | Division of Industrial Innovation & Partnerships
,
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
48 references, page 1 of 4

Head, E., Powell, D., Gold, B.T., Schmitt, F.A.. Alzheimer's Disease in DS. Eur J Neurodegener Dis. 2012; 1: 353-364 [OpenAIRE] [PubMed]

Ness, S., Rafii, M., Aisen, P., Krams, M., Silverman, W., Manji, H.. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012; 11: 655-656 [OpenAIRE] [PubMed]

Rafii, M.S., Wishnek, H., Brewer, J.B., Donohue, M.C., Ness, S., Mobley, W.C.. The Down Syndrome Biomarker Initiative (DSBI) Pilot: Proof of Concept for Deep Phenotyping of Alzheimer's Disease Biomarkers in Down Syndrome. Front Behav Neurosci. 2015; 9: 239 [OpenAIRE] [PubMed]

Drzezga, A., Lautenschlager, N., Siebner, H., Riemenschneider, M., Willoch, F., Minoshima, S.. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003; 30: 1104-1113 [OpenAIRE] [PubMed]

Mosconi, L., Mistur, R., Switalski, R., Tsui, W.H., Glodzik, L., Li, Y.. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009; 36: 811-822 [OpenAIRE] [PubMed]

Minoshima, S., Frey, K.A., Foster, N.L., Kuhl, D.E.. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995; 19: 541-547 [OpenAIRE] [PubMed]

Reiman, E.M., Caselli, R.J., Yun, L.S., Chen, K., Bandy, D., Minoshima, S.. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996; 334: 752-758 [OpenAIRE] [PubMed]

Protas, H.D., Chen, K., Langbaum, J.B., Fleisher, A.S., Alexander, G.E., Lee, W.. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 2013; 70: 320-325 [OpenAIRE] [PubMed]

Benzinger, T.L., Blazey, T., Jack, C.R., Koeppe, R.A., Su, Y., Xiong, C.. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013; 110: E4502-E4509 [OpenAIRE] [PubMed]

Alexander, G.E., Chen, K., Pietrini, P., Rapoport, S.I., Reiman, E.M.. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002; 159: 738-745 [PubMed]

Head, E., Silverman, W., Patterson, D., Lott, I.T.. Aging and DS. Curr Gerontol Geriatr Res. 2012; 2012: 412536 [OpenAIRE] [PubMed]

Head, E., Lott, I.T., Patterson, D., Doran, E., Haier, R.J.. Possible compensatory events in adult DS Brain prior to the Development of Alzheimer Disease neuropathology: Targets for non-pharmacological intervention. J Alzheimers Dis. 2007; 11: 61-76 [PubMed]

Lengyel, Z., Balogh, E., Emri, M., Szikszai, E., Kollar, J., Sikula, J.. Pattern of increased cerebral FDG uptake in DS patients. Pediatr Neurol. 2006; 34: 270-275 [PubMed]

Schapiro, M.B., Grady, C.L., Kumar, A., Herscovitch, P., Haxby, J.V., Moore, A.M.. Regional cerebral glucose metabolism is normal in young adults with DS. J Cereb Blood Flow Metab. 1990; 10: 199-206 [PubMed]

Haier, R.J., Alkire, M.T., White, N.S., Uncapher, M.R., Head, E., Lott, I.T.. Temporal cortex hypermetabolism in DS prior to the onset of dementia. Neurology. 2003; 61: 1673-1679 [OpenAIRE] [PubMed]

48 references, page 1 of 4
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2016

Dissociation of Down syndrome and Alzheimer's disease effects with imaging

Matthews, Dawn C.; Lukic, Ana S.; Andrews, Randolph D.; Marendic, Boris; Brewer, James; Rissman, Robert A.; Mosconi, Lisa; Strother, Stephen C.; Wernick, Miles N.; Mobley, William C.; ...